Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.
about
Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10Antibody vs. HIV in a clash of evolutionary titansComprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesPolyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individualsNeutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitorsCurrent Advances in Virus-Like Particles as a Vaccination Approach against HIV InfectionThe HIV glycan shield as a target for broadly neutralizing antibodiesStructural insights on the role of antibodies in HIV-1 vaccine and therapyA Blueprint for HIV Vaccine DiscoveryAntibody responses to envelope glycoproteins in HIV-1 infectionHIV-1 neutralizing antibodies: understanding nature's pathwaysHIV-1 antibodies from infection and vaccination: insights for guiding vaccine designAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesMutations that destabilize the gp41 core are determinants for stabilizing the simian immunodeficiency virus-CPmac envelope glycoprotein complexOptimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based DesignStructure of the HIV-1 gp41 Membrane-Proximal Ectodomain Region in a Putative Prefusion Conformation † , ‡A Conformational Switch in Human Immunodeficiency Virus gp41 Revealed by the Structures of Overlapping Epitopes Recognized by Neutralizing AntibodiesCrystallographic Definition of the Epitope Promiscuity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5: Vaccine Design ImplicationsRole of a Putative gp41 Dimerization Domain in Human Immunodeficiency Virus Type 1 Membrane FusionCrystal Structure of the Neutralizing Llama VHH D7 and Its Mode of HIV-1 gp120 InteractionStructural Characterization of HIV gp41 with the Membrane-proximal External RegionStructure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodiesStructural Basis of HIV-1 Neutralization by Affinity Matured Fabs Directed against the Internal Trimeric Coiled-Coil of gp41Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 BindingFocused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep SequencingBroad and potent neutralization of HIV-1 by a gp41-specific human antibodyStructure-Based Design of a Protein Immunogen that Displays an HIV-1 gp41 Neutralizing EpitopeViral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization BreadthA gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen RecognitionAutoreactivity and Exceptional CDR Plasticity (but Not Unusual Polyspecificity) Hinder Elicitation of the Anti-HIV Antibody 4E10Structural Basis for HIV-1 Neutralization by 2F5-Like Antibodies m66 and m66.6Structure and Immunogenicity of a Peptide Vaccine, Including the Complete HIV-1 gp41 2F5 EpitopeStructure of an HIV-1-neutralizing antibody target, the lipid-bound gp41 envelope membrane proximal region trimerStructural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers.Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory AntibodiesThe good and evil of complement activation in HIV-1 infectionInsensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype BV3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodiesNeutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India
P2860
Q21089590-A7544664-D4C0-4C7F-926D-24691EE6AFA8Q24536059-572863C2-E2B4-4684-81EC-272C528807C6Q24561905-B79C21A9-ADE5-4BDE-89F8-51DA59394002Q24635002-BFA0D13F-341E-41A7-80D6-DB851D5F10C7Q24655129-ABFCB53C-32BC-4C8D-9414-28C0AC27D1D7Q26775082-B890F33A-1784-4635-94D8-32EB8403EC7CQ26786540-CBDF2E44-52CF-4A33-8BFA-E1A434C6D2A4Q26829461-C99C18E1-81D4-47E7-969B-E2AEF7CAC8D8Q26829865-16053223-F271-4030-A554-707B44C12F8FQ26991572-FE1D8B03-6AC3-4CD3-8FB5-E0327910619CQ27000480-E6FABCAE-0806-4A95-BA47-F2D5C0EEA0C5Q27022055-EA89A6EC-4D78-4AB0-8692-19643637170BQ27489000-44C15B06-7C0C-4DDA-8BAA-6C752B647F58Q27637675-2A708D06-E2C2-4149-AD7F-6BDA0FDFD1CCQ27644646-94E4AB64-0A6B-4FED-A5A4-173F1F0DC5A3Q27653846-92706777-808E-48BC-97D8-2632931D3A1CQ27655865-65BEFF52-5861-46D8-9F01-FD2467C541C2Q27657377-AE6A0D5E-8270-449D-A382-8734FB3C71C2Q27657871-10BB5BC6-85DB-4AF1-9933-187CAA7377CFQ27661588-937B60B3-FC4E-4784-A7D2-AF388F4B6EE2Q27662117-C5F316DB-6B70-461A-903F-AEE2E4EF32F5Q27662155-73B97358-6563-47EE-974C-50FA5B66443CQ27665884-6AFA664C-B492-4B44-B948-F8709A16AEBAQ27665960-E5BE5EE5-3F8A-4D8A-BA9D-245BB00E8503Q27670829-8C18CA37-D8E4-4F03-BEFF-241CB88CE725Q27671696-F601762E-B95D-46D9-9755-218E649B68F5Q27675131-34CB8435-EBF7-41F6-B0F9-D5F47F7AC686Q27675260-24E02C84-414D-40A7-8302-195DD6F82A99Q27676728-1172EFEA-5991-46DC-9D20-89CE903840E1Q27676864-A5E97C41-70CD-4333-BB81-1F8B35556B5AQ27680125-51B3290F-1B34-4CB6-8795-19F260BE6620Q27680872-4534B1B3-80D3-4603-95AC-F165247E3316Q27681352-37622E1D-86D4-4A84-984E-A76B03D2BB6BQ27681501-11213B7A-140A-42A4-8F79-353B4A3155B0Q27683553-8D332AE2-B250-49F4-A709-E71F6B20AA53Q28066335-E46435A2-6B6A-47DB-8EB1-F40B9B765E55Q28275986-B62A5553-A270-400D-8364-087DF3695A06Q28469023-792B3EFB-9243-4B02-8DAC-89CA7F771BE4Q28469283-7A2156A2-2F2B-4F89-8527-249AB1309A0EQ28483205-0E476875-01E3-4AC5-B1D2-452AA5B7B260
P2860
Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Broadly neutralizing antibodie ...... irus type 1 glycoprotein gp41.
@ast
Broadly neutralizing antibodie ...... irus type 1 glycoprotein gp41.
@en
type
label
Broadly neutralizing antibodie ...... irus type 1 glycoprotein gp41.
@ast
Broadly neutralizing antibodie ...... irus type 1 glycoprotein gp41.
@en
prefLabel
Broadly neutralizing antibodie ...... irus type 1 glycoprotein gp41.
@ast
Broadly neutralizing antibodie ...... irus type 1 glycoprotein gp41.
@en
P2093
P2860
P1433
P1476
Broadly neutralizing antibodie ...... irus type 1 glycoprotein gp41.
@en
P2093
A F Labrijn
C Spenlehauer
D R Burton
G Stiegler
H Katinger
J M Binley
P2860
P304
10892-10905
P356
10.1128/JVI.75.22.10892-10905.2001
P577
2001-11-01T00:00:00Z